For Healthcare Professionals:

Genetic Obesity ID | GENOTYPING STUDY:
An IRB-approved genetic screening study for individuals suspected of POMC or LEPR deficiency obesity

We invite you to register to participate in this new genotyping study that is screening people for obesity resulting from either POMC (pro-opiomelanocortin) or LEPR (leptin receptor) deficiency—two rare but important types of genetic, early-onset obesity. The goal of the Genetic Obesity ID/ Genotyping Study is to develop a screening algorithm for selecting patients to be genotyped and diagnosed with POMC and LEPR deficiency. Study investigators are located in both the US and EU.

Registering to participate in this study requires the completion of a questionnaire survey that aims to determine the demographic characteristics of the patients you have seen in your practice who match the clinical profile of POMC or LEPR deficiency obesity but who have not undergone genetic testing. Our goals are to:

  • Identify patients who may be candidates for the genotyping studies
  • Obtain an estimate of the number of suspected patients without a confirmed genetic diagnosis

If you have seen patients whose presentation is consistent with either of these disorders, we would be very interested in hearing from you. We are initiating this genotyping study in both the US and Europe in coming months and will contact you if there is potential for your patient (s) to participate in this study.

Register for more information about participating in the POMC / LEPR Obesity Genotyping Study

This program is supported by Rhythm, a Boston-based biopharmaceutical company developing the MC4R peptide agonist, setmelanotide (RM-493), for obesity caused by genetic deficiencies in the MC4 pathway.
Back to Top